A House committee is set to vote on proposals that would tighten China investment and in-licensing restrictions, including adding BINSA-research restrictions and domestic biomanufacturing support to the NDAA. The move reflects mounting US scrutiny of licensing arrangements involving Chinese biotechnology assets. The rulemaking is aimed at national-security and competitive concerns, with lawmakers arguing that the biotech ecosystem may be exposed when Chinese-origin assets become embedded in strategic pipeline portfolios. The committee action would add formal compliance hurdles to certain cross-border deal structures. Companies with ongoing licensing and collaborations will be watching for how definitions of covered transactions are drawn and what carveouts—if any—are included. The outcome could quickly reshape BD strategy, venture funding timelines, and how investors underwrite China-linked pipeline risk.